Clinical trial
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III…
NCT00004175 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00004175 |
|---|---|
| Title | Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer |
| Official title | Phase II Study of Taxotere, Doxorubicin and Cyclophosphamide (TAC) Primary Therapy in Stage III Breast Cancer |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | cyclophosphamide, docetaxel, doxorubicin hydrochloride, conventional surgery |
| Start date | Nov 1, 1998 |
| Primary completion | Sep 1, 2004 |
| Completion | Jun 1, 2005 |
| First posted | Mar 3, 2004 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: